Abstract-Characteristics of the interaction of verapamil with serotonin receptors were studied in rat brain membranes using a radioligand binding technique.
Although verapamil is known as a proto type of calcium entry blockers, several recent studies related with radioligand binding have indicated that verapamil may possess the action of blocking certain types of mem brane receptors in addition to the calcium channel blocking effect. For example, verapamil is a competitive inhibitor of radio ligand binding to alpha-adrenoceptors and muscarinic acetylcholine receptors in rat myocardium (1) , rat kidney (2) and human platelets (2) . In regard to serotonin (5- and in the washed membranes ( Fig. 2) In regard to the cardiovascular actions of serotonin, 5-HT, and 5-HT2 receptors has been suggested to mediate vascular relaxation and contraction, respectively (9) . Platelet aggregation has also been reported to be mediated by 5-HT2 receptors (10) . In functional studies, Angus and Brazenor (11) reported selective relaxing actions of verapamil and D600 in canine coronary arteries contracted by serotonin. The (-) isomers of both compounds were more potent (seven to 26-fold) than the (+) isomers. In rabbit isolated aorta, Auguet et al. (12) and Ohashi et al. (13) reported competitive inhibitions of the contractile response to serotonin by D600 and by D600 and diltiazem, respectively. Interestingly, the negative logarithm of the K, values for D600 and diltiazem in the present study (6.55 and 5.04, respectively) agreed quite well with the pA2 values for these compounds in the paper of Ohashi et al. (6.56 and 5.05, respectively). Affolter et al. (4) reported inhibitions of the serotonin-induced shape change reaction of human platelets by verapamil and D600 in therapeutic concentrations. The inhibitory action of verapamil was independent of external Cat', and neither nitrendipine nor diltiazem had any effect on this reaction.
Taking into consideration the results obtained in the present binding study together with the experimental findings from the above-mentioned functional studies, we suggest that the antagonistic action of verapamil on 5-HT2 receptors on vascular smooth muscles and platelets, in addition to its calcium antagonistic action, may con tribute to its therapeutic effects. The close relation between the K; value (410 nM) of verapamil for the competition with [3H] ketanserin binding obtained in the present study and the reported therapeutic concen tration of verapamil (100-400 ng/ml or 200 800 nM) (14) may further support this possibility.
